Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 10/20 | 0.75 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.47 |
| ▸ | RXRA | P19793 | 3/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26539324 | 0.93 | CYP1A2 (0.74) | CYP1A2SCN5ARXRAGRIN1GRIN2B | |
| SCHEMBL21835657 | 0.87 | CYP1A2 (0.83) | CYP1A2SCN5ARXRAGRIN1GRIN2B | |
| SCHEMBL20203811 | 0.86 | CYP1A2 (0.76) | CYP1A2SCN5ARXRAGRIN1GRIN2B | |
| SCHEMBL20203838 | 0.86 | CYP1A2 (1.00) | CYP1A2SCN5ARXRAGRIN1GRIN2B | |
| SCHEMBL31733960 | 0.85 | CYP1A2 (0.87) | CYP1A2SCN5ARXRAGRIN1GRIN2B | |
| SCHEMBL26539129 | 0.85 | CYP1A2 (0.87) | CYP1A2SCN5ARXRAGRIN1GRIN2B | |
| SCHEMBL20203886 | 0.85 | CYP1A2 (0.77) | CYP1A2SCN5ADYRK1AALOX5APFEN1 | |
| SCHEMBL20203709 | 0.85 | CYP1A2 (1.00) | CYP1A2SCN5ADYRK1AAAK1ALOX5AP | |
| SCHEMBL24155936 | 0.84 | CYP1A2 (0.85) | CYP1A2SCN5ARXRAGRIN1GRIN2B | |
| SCHEMBL21835764 | 0.84 | CYP1A2 (0.85) | CYP1A2SCN5ARXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2021-06-24 | — | — | US | disclosed |
| WO-2018098499-A1 | COMPOUNDS AND THEIR METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188852-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885RXRA 2238/4885 |
| US-20230322790-A1 | COMPOUNDS AND THEIR METHODS OF USE | SCN1A, SCN3A, SCN1B | CYP1A2 1988/4885SCN5A 8/4885RXRA 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.